Trial	Phase	Sponsor	Dist.
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)	Phase 3	Karuna Therapeutics	<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics	<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	<1 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	<1 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)	Phase 3	Bristol-Myers Squibb	<1 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)	Phase 3	Bristol-Myers Squibb	<1 mi
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia	Early 1	University of Texas at Austin	<1 mi
Paper-Based and Smartphone-Based Memory Supports	N/A	Baylor University	<1 mi
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD	Phase 3	Annovis Bio Inc.	<1 mi
Remotely-supervised Neuromodulation in PPA	N/A	University of Texas at Austin	<1 mi
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease	Phase 4	University of Texas at Austin	<1 mi
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia	N/A	University of Texas at Austin	<1 mi
Clinical Trial on Agitation in Alzheimer's Dementia	Phase 2	IGC Pharma, LLC	<1 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease	Phase 2	Intra-Cellular Therapies, Inc.	<1 mi
Advancing Alzheimer's Care: Home-based tDCS for Affective Symptoms	N/A	The University of Texas Health Science Center at San Antonio	<1 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)	—	University of Southern California	<1 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia	Phase 2	Intra-Cellular Therapies, Inc.	<1 mi
Rapamycin - Effects on Alzheimer's and Cognitive Health	Phase 2	The University of Texas Health Science Center at San Antonio	<1 mi
δ in Dementia Clinical Trials	N/A	The University of Texas Health Science Center at San Antonio	<1 mi
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)	Phase 1/2	AC Immune SA	<1 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)	Phase 3	Bristol-Myers Squibb	<1 mi
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Phase 3	Suven Life Sciences Limited	<1 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies	Phase 3	Hoffmann-La Roche	<1 mi
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)	—	University of Southern California	<1 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	<1 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)	Phase 3	Karuna Therapeutics	<1 mi
ACP-204 in Adults With Alzheimer's Disease Psychosis	Phase 2/3	ACADIA Pharmaceuticals Inc.	<1 mi
Smartphone-based Cognitive Emotion Regulation Training for Unpaid Primary Caregivers of Persons With Alzheimer's Disease	N/A	Bryan Denny	<1 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol	—	Indiana University	<1 mi
Stem Cell Therapy for Early Alzheimer's Disease	Phase 1/2	Paul E Schulz	<1 mi
Systemic and Central Inflammation in AD	Phase 2	The Methodist Hospital Research Institute	<1 mi
Phase II Clinical Trial of Interleukin-2 in AD	Phase 2	The Methodist Hospital Research Institute	<1 mi
Epidemiology and Biomarker Study in Alzheimer's Disease	Phase 3	Eli Lilly and Company	<1 mi
Open-label Extension Study in Participants With Early Alzheimer's Disease	Phase 2	GlaxoSmithKline	<1 mi
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease	Early 1	Baylor College of Medicine	<1 mi
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia	—	GAP Innovations, PBC	<1 mi
Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease	N/A	Baylor College of Medicine	<1 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	<1 mi
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)	Phase 2	Rong Zhang	<1 mi
[18F]PI-2620 Phase 3 Histopathological Study	Phase 3	Life Molecular Imaging Ltd	<1 mi
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)	Phase 2	Merck Sharp & Dohme LLC	<1 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	<1 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	<1 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)	Phase 3	Bristol-Myers Squibb	<1 mi
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease	N/A	InSightec	<1 mi
Late Onset Alzheimer's Disease	—	Columbia University	<1 mi
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)	Phase 2	Alzheimer's Disease Cooperative Study (ADCS)	2 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)	Phase 2	Merck Sharp & Dohme LLC	24 mi
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase	N/A	University of Alabama, Tuscaloosa	29 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.